DURACON CS TIBIAL INSERT

K021451 · Howmedica Osteonics Corp. · JWH · Oct 18, 2002 · Orthopedic

Device Facts

Record IDK021451
Device NameDURACON CS TIBIAL INSERT
ApplicantHowmedica Osteonics Corp.
Product CodeJWH · Orthopedic
Decision DateOct 18, 2002
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3560
Device ClassClass 2
AttributesTherapeutic

Intended Use

The Duracon® CS (Condylar Stabilizing) Tibial Inserts are intended to be used with Duracon® Universal and Cruciform tibial baseplates, Duracon® Cruciate Retaining femoral components and Duracon® patellar components as part of a total knee system in primary cemented total knee arthroplasty. These inserts are intended to be used in cases where there is destruction of the joint surfaces with or without bone deformity, where the cruciate ligaments are inadequate, not present, or cannot be preserved during the operative procedure, especially when anterior-posterior stability is impaired due to absence of the patella. The collateral ligaments should be intact if this insert is utilized. Because this insert does not incorporate a support post, it can accommodate the posterior cruciate ligament if it is present.

Device Story

Ultra-high molecular weight polyethylene tibial insert for total knee arthroplasty; used with Duracon® femoral, tibial, and patellar components. Features dished articulating surface for anatomic rollback, flexion-extension, and internal-external rotation; includes raised anterior eminence for anterior constraint when posterior cruciate ligament (PCL) is absent. Design lacks support post, allowing accommodation of PCL if present. Used in clinical settings by orthopedic surgeons. Provides 37% more constraint than predicate Duracon® AP Lipped Tibial Insert without increasing rotational constraint. Benefits patients by restoring joint function and stability in cases of joint surface destruction or ligamentous inadequacy.

Clinical Evidence

Bench testing only. No clinical data provided.

Technological Characteristics

Ultra-high molecular weight polyethylene tibial insert. Available in multiple sizes (small, medium, large, extra-large) and thicknesses (9mm to 25mm). Features dished articulating surface and raised anterior eminence. Designed for use with Duracon® Universal and Cruciform tibial baseplates. Cemented fixation. No support post. Mechanical design provides anatomic rollback and constraint.

Indications for Use

Indicated for patients with noninflammatory degenerative joint disease (osteoarthritis, traumatic arthritis, avascular necrosis), rheumatoid arthritis, functional deformity, post-traumatic loss of joint anatomy (patello-femoral erosion/dysfunction, prior patellectomy), or irreparable knee fracture. Contraindicated in patients with overt infection, distant foci of infection, rapid disease progression, skeletal immaturity, or poor bone stock. Conditions increasing failure risk include uncooperative patients, neurological disorders, osteoporosis, metabolic bone disorders, osteomalacia, and previous arthrodesis.

Regulatory Classification

Identification

A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).

Predicate Devices

Reference Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ p//3 K021451 Duracon® CS Lipped Tibial Insert_ Confidential 510(k) Premarket Notification OCT 1 8 2002 | 510(k) Summary | | |------------------------------------|-----------------------------------------------------------------------------------------------------------------------| | Submission Information | | | Name and Address of Sponsor: | Howmedica Osteonics Corp.<br>59 Route 17<br>Allendale, NJ 07401 | | For Information contact: | Margaret F. Crowe<br>Regulatory Affairs Consultant<br>Howmedica Osteonics Corp.<br>59 Route 17<br>Allendale, NJ 07401 | | Device Identification | | | Proprietary Name: | Duracon® CS Tibial Insert | | Common Name: | Polyethylene Tibial Insert | | Classification Name and Reference: | Knee Joint Patellofemorotibial<br>Polymer/Metal/Polymer Semi-Constrained<br>Cemented Prosthesis<br>21 CFR §888.3560 | | Proposed Regulatory Class: | Class II | | Device Product Code: | OR(87) | | | JWH<br>Prosthesis, Knee Patellofemorotibial, Semi-<br>Constrained, Cemented, Polymer/Metal/ Polymer | The Duracon® CS (Condylar Stabilizing) Tibial Inserts are intended to be used with Duracon® Universal and Cruciform tibial baseplates, Duracon® Cruciate Retaining femoral components and Duracon® patellar components as part of a total knee system in primary cemented total knee arthroplasty. These inserts are intended to be used in cases where there is destruction of the joint surfaces with or without bone deformity, where the cruciate ligaments are inadequate, not present, or cannot be preserved during the operative procedure, especially when anterior-posterior stability is impaired due to absence of the patella. The collateral ligaments should be intact if this insert is utilized. 2 {1}------------------------------------------------ Duracon® CS Lipped Tibial Insert Confidential This tibial insert may also be used in situations where the posterior cruciate ligament is present - its geometry will accommodate that ligament. More specific indications and contraindications are listed below: ### Indications - Noninflammatory degenerative joint disease including osteoarthritis, traumatic I arthritis or avascular necrosis, - 트 Rheumatoid arthritis, - 지 Correction of functional deformity, - Post-traumatic loss of joint anatomy, particularly when there is patello-femoral . erosion, dysfunction or prior patellectomy; and, - . Irreparable fracture of the knee #### Contraindications Absolute contraindications include: - 트 Overt infection, - Distant foci of infections (which may cause hematogenous spread to the implant site), 대 - Rapid disease progression as manifested by joint destruction or bone absorption T apparent on roentgenogram, - . Skeletally immature patients - Cases where there is poor bone stock which would make the procedure unjustifiable, 피 Conditions presenting an increased risk of failure include: - Uncooperative patient or patient with neurological disorders who is incapable of . following instructions, - Osteoporosis, . - Metabolic disorders which may impair bone formation, - 내 Osteomalacia, and - Previous arthrodesis The subject Duracon® CS Tibial Insert is an ultra-high molecular weight polyethylene tibial insert designed to be used with the femoral, tibial, and patellar components of the {2}------------------------------------------------ # K021451 ## Duracon® CS Lipped Tibial Insert______________________________________________________________________________________________________________________________________________ Confidential #### 510(k) Premarket Notification Duracon® Total Knee System. This insert is available in small, medium, large, and extralarge sizes in the following thicknesses: 9mm, 11mm, 16m, 19mm, 22mm, and 25mm. The subject insert has a dished articulating surface geometry to provide anatomic rollback, flexion-extension and internal-external rotation. The subject tibial insert features a raised anterior eminence designed to provide greater anterior constraint in situations where the posterior cruciate ligament is not present or not functional. This anterior eminence is designed to provide substitution for the posterior cruciate ligament if it is not present or cannot be preserved. The subject insert provides approximately 37 percent more constraint than the predicate Duracon® AP Lipped Tibial Insert, without any increase in rotational constraint. The subject insert does not feature a support post. This allows the Duracon® Condylar Stabilizing (CS) Lipped Tibial Insert to be used with the Duracon® Condylar Femoral Components. These condylar femoral components do not require the removal of additional bone from the distal surface of the femur. Because this insert does not feature a support post, it may also be used in situations where the posterior cruciate ligament is present. The geometry of the insert will accommodate the PCL if it is present. The subject Duracon® CS Tibial Insert features the same locking mechanism as the previously released Duracon® Condylar and AP Lipped Tibial Insert. Testing was presented to characterize the function of the subject tibial insert, and to demonstrate substantial equivalence to other legally marketed devices. {3}------------------------------------------------ #### DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus, which is a symbol often associated with medicine and healthcare. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" are arranged in a circular pattern around the caduceus. #### Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Ms. Margaret F. Crowe Regulatory Affairs Consultant Howmedica Osteonics Corporation 59 Route 17 Allendale, New Jersey 07401 Re: K021451 Trade/Device Name: Duracon® CS Lipped Tibial Insert Regulation Number: 21 CFR §888.3560 Regulation Name: Knee joint patellofemorotibial polymer/metal/polymer semiconstrained cemented prosthesis Regulatory Class: Class II Product Code: JWH Dated: August 2, 2002 Received: August 5, 2002 Dear Ms. Crowe: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {4}------------------------------------------------ #### Page 2 - Ms. Margaret F. Crowe Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, Mark N McKesson Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ Duracon® CS Lipped Tibial Insert 510(k) Premarket Notification Confidential 510(k) Number (if known): KO2(45) Duracon® CS Lipped Tibial Insert Device Name: The Duracon® CS (Condylar Stabilizing) Tibial Inserts are intended to be used with Duracon® Universal and Cruciform tibial baseplates, Duracon® Cruciate Retaining femoral components and Duracon® patellar components as part of a total knee system in primary cemented total knee arthroplasty. These inserts are intended to be used in cases where there is destruction of the joint surfaces with or without bone deformity, where the cruciate ligaments are inadequate, not present, or cannot be preserved during the operative procedure, especially when anterior-posterior stability is impaired due to absence of the patella. The collateral ligaments should be intact if this insert is utilized. Because this insert does not incorporate a support post, it can accommodate the posterior cruciate ligament if it is present. More specific indications/contraindications are listed below: #### Indications - Noninflammatory degenerative joint disease including osteoarthritis, traumatic I arthritis or avascular necrosis, - Rheumatoid arthritis, - 비 Correction of functional deformity, - Post-traumatic loss of joint anatomy, particularly when there is patello-femoral 미 erosion, dysfunction or prior patellectomy; and, - Irreparable fracture of the knee (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use OR 801.109) Over the Counter Use - per CFR (Division Sign-Off) Division of General, Restorative and Neurological Devices 510(k) Number -
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%